Wave Life Sciences Earns $12 Million Milestone as GSK Advances Liver Drug

MT newswire2026/09/30 11:59

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

07:59 AM EDT, 09/30/2026 (MT Newswires) -- Wave Life Sciences (WVE) said Wednesday that GSK (GSK) selected a liver disease drug candidate from their research partnership to advance into its development pipeline. Wave will receive a $12 million milestone payment and remains eligible for up to $375 million in development and commercial milestones per project, along with tiered sales royalties, the company said. Wave Life Sciences is advancing three other joint programs toward potential candidate selection, the company said. Shares of Wave Life Sciences were up 7.4% in Wednesday premarket activity.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

According to media reports, the capacity review work by OPEC+ has been delayed. Originally scheduled to be completed by the end of September 2026, it has now been postponed to mid-November. This theoretically still allows OPEC+ to discuss the related results at the plenary meeting in late November. The independent capacity assessment results will directly affect the production caps approved for each member country, and some member countries have already shown significant disagreements regarding quotas, putting pressure on the alliance’s stability.

华尔街见闻•2026/10/02 16:36

BUZZ-KeyBanc gives SailPoint an “Industry Weight” rating for the first time; stock price slightly declines

路透社•2026/10/02 16:31

71% of UK finance leaders expect tokenization to reshape financial services: Lloyds

Cointelegraph•2026/10/02 16:28